Anticipate Submission for Label Extension in First Half 2022 YAVNE, Israel , Nov. 18, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today

Third Quarter Revenues of $6.4   Million ; Year-to-Date 2021 Revenues Increased 21% C larity on   R egulatory P athway for R esubmission of NexoBrid BLA , A nticipated in M id- 2022 EscharEx Phase 2 Program Top-Line Results Accelerated, Currently Expected in the First Quarter of 2022 Conference

YAVNE, Israel , Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the third

EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar YAVNE, Israel , Oct. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today

YAVNE, Israel , Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at the following

Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year Positive Interim Assessment Outcome for EscharEx U.S. Phase II Clinical Study No Changes to Study Sample Size – No Safety Concerns Identified Conference call begins today at 8:30 am ET   YAVNE, Israel , Aug.

YAVNE, Israel , Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the second

Independent Data Monitoring Committee R ecommends C ontinuation of the Study with N o   C hanges to Study Sample Size No Safety Concerns Identified Full Study   Enrollment Expected by Year-End 2021; D ata R eadout E xpected in t he F irst H alf of 2022 YAVNE, Israel , July 28, 2021 (GLOBE NEWSWIRE)

Data Expected End of 2021 Phase II Investigator-Initiated Trial in Non-Melanoma Skin Cancers Running in Parallel YAVNE, Israel , July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for

Primary Endpoints Met with Highly Statistically Significant Results Compared with Standard-of-Care YAVNE, Israel , July 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair